Healthcare services group Uniphar has reported higher revenues and profits for the year to the end of December and said it remains confident of achieving its target of €200m EBITDA by 2028.
Uniphar said its revenues rose by 11% to €3.075 billion, while profit before tax - excluding expectations - was up 17.4% to €71.79m from €61.13m the previous year.
The owner of Hickey's, McCauley, Allcare and Life Pharmacies also reported organic gross profit growth of 8.9%, the fastest growth rate achieved since its IPO.
It noted that organic growth was seen across all its divisions with a particularly strong performance from the Pharma and Medtech divisions, which posted organic growth of 15.5% and 10.5% respectively.
Uniphar reported adjusted earnings per share growth of 21% to 24.8 cent, which it said came on the back of the positive impact of lower finance costs and the accretive benefit of the €35m share buyback in the year.
Its total dividend for the year came to €5.2m (€0.0202 per ordinary share), which marked a 5.2% per share increase year-on-year. This includes a €1.8m interim (€0.0071 per ordinary share) dividend paid in October and a final dividend of €3.4m (€0.0131 per ordinary share) subject to approval at the AGM.
Ger Rabbette, Uniphar Group's chief executive, said he was pleased with the results the group delivered in 2025, achieving its fastest rate of organic gross profit growth since IPO at 8.9%, alongside adjusted EPS growth of 21%.
"Over the past six years, we have delivered excellent compound annual adjusted EPS growth of 16%. These results reflect the successful execution of our strategy across all divisions and our continued ability to scale and generate sustainable growth," he said.
"We remain confident of achieving our target of €200m EBITDA by 2028 with at least 80% of that growth being delivered organically," he added.
Breaking down its divisions, the company said that its Uniphar Pharma unit posted 15.5% organic gross profit growth, with the "excellent" performance driven by strong growth in Global Sourcing and clinical trial supply.
Its Uniphar Medtech division saw 10.5% organic gross profit growth, on the back of sustained growth in core markets, geographic expansion with existing suppliers and the rollout of new suppliers across established regions.
Meanwhile, the Uniphar Supply Chain & Retail division reported 4.2% organic Gross Profit growth, due to strong volume growth in the Supply Chain division.
The retail pharmacy network expanded by 37 to 482 pharmacies in the year, Uniphar added.
Shares in the company were higher in Dublin trade today.
